|
|
Volumn 356, Issue , 2017, Pages j845-
|
|
Merck ends trial of potential Alzheimer's drug verubecestat
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADUCANUMAB;
AMYLOID;
MONOCLONAL ANTIBODY;
NOOTROPIC AGENT;
SULFOXIDE;
THIADIAZINE DERIVATIVE;
VERUBECESTAT;
ALZHEIMER DISEASE;
CEREBROSPINAL FLUID;
CLINICAL TRIAL (TOPIC);
DRUG EFFECTS;
DRUG INDUSTRY;
HUMAN;
PROCEDURES;
SEVERITY OF ILLNESS INDEX;
ALZHEIMER DISEASE;
AMYLOID;
ANTIBODIES, MONOCLONAL, HUMANIZED;
CLINICAL TRIALS AS TOPIC;
CYCLIC S-OXIDES;
DRUG INDUSTRY;
HUMANS;
NOOTROPIC AGENTS;
SEVERITY OF ILLNESS INDEX;
THIADIAZINES;
|
|
EID: 85016405305
PISSN: None
EISSN: 17561833
Source Type: Journal
DOI: 10.1136/bmj.j845 Document Type: Article |
|
Times cited : (51)
|
|
References (0)
|